Liver triglyceride content in HIV-1-infected patients on combination antiretroviral therapy studied with 1H-MR spectroscopy

Antiviral Therapy

Volumn 12, Issue 2, 2007, Pages 195-203

  Moreno Torres, Angel ^a   Domingo, Pere ^b   Pujol, Jesus ^a,c   Blanco Vaca, Francisco ^b   Arroyo, Juan Antonio ^b   Sambeat, Ma Antonia ^b  

^a Centre Diagnostic Pedralbes   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c Institut d'Alta Tecnologia   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD CHEMISTRY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LIVER LEVEL; MALE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; STEATOSIS;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FATTY LIVER; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LIVER; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; TRIGLYCERIDES; TRITIUM;

EID: 34147103413     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Carr A. Toxicity of antiretroviral therapy and implications for drug development. Nat Rev Drug Discov 2003; 2:624-634.
2. Montessori V, Press N, Harris M, Akagi L, Montaner JS. Adverse effects of antiretroviral therapy for HIV infection. Can Med Assoc J 2004; 170:229-238.
3. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607.
4. Gazzaruso C, Sacchi P, Garzaniti A, Fratino P, Bruno R, Filice G. Prevalence of metabolic syndrome among HIV patients. Diabetes Care 2002; 25:1253-1254.
5. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24:683-689.
6. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 1992; 41:715-722.
7. Lonergan J, Behling C, Pfander H, Hassanein T, Mathews S. Hyperlactatemia and hepatic abnormalities in 10 HIV infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis 2000; 31:162-166.
8. Sutinen J, Hakkinen AM, Westerbacka J, et al. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS 2002; 16:2183-2193.
9. Ruhl CE, Everhart JE. Epidemiology of nonalcoholic fatty liver. Clin Liver Dis 2004; 8:501-519.
10. 1H localized magnetic resonance spectroscopy and comparison with computed tomography. Invest Radiol 1993; 28:297-302.
11. Thomsen C, Becker U, Winkler K, Chrisroffersen P, Jensen M, Henriksen O. Quantification of liver fat using magnetic resonance spectroscopy. Magn Reson Imaging 1994; 12:487-495.
12. Szczepaniak LS, Babcock EE, Schick F, et al. Measurement of intracellular triglyceride stores by 1H spectroscopy: validation in vivo. Am J Physiol 1999; 276:E977-E989.
13. Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005; 288:E462-E468.
14. Westerbacka J, Lammi K, Hakkinen AM, et al. Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab 2005; 90:2804-2809.
15. Schonfeld G, Patterson BW, Yablonskiy DA, et al. Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis. J Lipid Res 2003; 44:470-478.
16. den Boer M, Voshol PJ, Kuipers F, Havekes LM, Romijn JA. Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. Arterioscler Thromb Vasc Biol 2004; 24:644-649.
17. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of non-alcoholic fatty liver disease to insulin resistance. Am J Med 1999; 107:450-455.
18. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50:1844-1850.
19. Ryysy L, Hakkinen AM, Goto T, et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000; 49:749-758.
20. Lemieux S, Prud'homme D, Bouchard C, Tremblay A, Despres JP. A single threshold of waist girth identifies normal-weight and overweight subjects with excess visceral adipose tissue. Am J Clin Nutr 1996; 64:685-693.
21. Christeff N, Melchior JC, de Truchis P, Perronne C, Nunez EA, Gougeon ML. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations. AIDS 1999; 13:2251-2260.
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment. Diabetologia 1985; 28:412-419.
23. Ascaso JF, Romero P, Real JT, Priego A, Valdecabres C, Carmena R. Insulin resistance quantification by fasting insulin plasma values and HOMA index in a non-diabetic population. Med Clin (Barc) 2001; 117:530-533.
24. Ascaso JF, Romero P, Real JT, Lorente RI, Martinez-Valls J, Carmena R. Abdominal obesity, insulin resistance, and metabolic syndrome in a southern European population. Eur J Intern Med 2003; 14:101-106.
25. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998; 15:539-553.
26. Korin HW, Ehman RL, Riederer SJ, Felmlee JP, Grimm RC. Respiratory kinematics of the upper abdominal organs: a quantitative study. Magn Reson Med 1992; 23:172-178.
27. Frahm J, Merboldt KD, Hänicke W. Localised proton spectroscopy using stimulated echoes. J Magn Reson 1987; 72:502-508.
28. Moreno-Torres A, Pujol J, Soriano-Mas C, Deus J, Iranzo A, Santamaria J. Age-related metabolic changes in the upper brainstem tegmentum by MR spectroscopy. Neurobiol Aging 2005; 26:1051-1059.
29. Katz-Brull R, Rofsky NM, Lenkinski RE. Breathhold abdominal and thoracic proton MR spectroscopy at 3T. Magn Reson Med 2003; 50:461-467.
30. 31P NMR signals using the variable projection method and prior knowledge. Magn Reson Med 1988; 6:92-98.
31. Hoyumpa AM Jr, Greene HL, Dunn GD, Schenker S. Fatty liver: biochemical and clinical considerations. Am J Dig Dis 1975; 20:1142-1170.
32. Piroth L. Liver steatosis in HIV-infected patients. AIDS Rev 2005; 7:197-209.
33. Pares A, Tresserras R, Nunez I, et al. Prevalence and factors associated to the presence of fatty liver in apparently healthy adult men. Med Clin (Barc) 2000; 114:561-565.
34. Thomopoulos KC, Arvaniti V, Tsamantas AC, et al. Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis. Eur J Gastroenterol Hepatol 2006; 18:233-237.
35. Sulkowski MS, Mehta SH, Torbenson M, et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005; 19:585-592.
36. Krai JG, Schaffner F, Pierson RN Jr, Wang J. Body fat topography as an independent predictor of fatty liver. Metabolism 1993; 42:548-551.
37. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30:1356-1362.
38. Murphy DJ. The biogenesis and functions of lipid bodies in animals, plants and microorganisms. Prog Lipid Res 2001; 40:325-438.
39. Nolan D. Metabolic complications associated with HIV protease inhibitor therapy. Drugs 2003; 63:2555-2574.
40. Carpentier A, Patterson BW, Uffelman KD, Salit I, Lewis GF. Mechanism of highly active anti-retroviral therapy-induced hyperlipidemia in HIV-infected individuals. Atherosclerosis 2005; 178:165-172.
41. Riddle TM, Kuhel DG, Woollett LA, Fichtenbaum CJ, Hui DY. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem 2001; 276:37514-37519.
42. Sanyal AJ. Mechanisms of Disease: pathogenesis of nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2005; 2:46-53.
43. Brinkman K. Editorial Response: Hyperlactatemia and Hepatic Steatosis as Features of Mitochondrial Toxicity of Nucleoside Analogue Reverse Transcriptase Inhibitors. Clin Infect Dis 2000; 31:167-169.
44. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23:57-63.
45. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28:2289-2304.
46. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 2005; 366:1059-1062.